Allogene Therapeutics will hold a conference call on August 13, 2025, to discuss Q2 financial results and business updates.
Quiver AI Summary
Allogene Therapeutics, Inc., a biotechnology company based in South San Francisco that focuses on developing allogeneic CAR T products for cancer and autoimmune diseases, announced it will release its second quarter 2025 financial results and provide a business update on August 13, 2025, after market close. Following the announcement, a live audio webcast and conference call will take place at 2:00 p.m. PT/5:00 p.m. ET, with details available on the company’s website. Those wishing to ask questions during the call can register to receive a personal PIN. The company highlighted its mission to provide effective and scalable CAR T cell therapies and included a cautionary note regarding forward-looking statements, detailing potential risks and uncertainties inherent in their developmental processes.
Potential Positives
- Allogene Therapeutics is set to provide important updates on its financial results and business developments, which can enhance transparency and investor confidence.
- The scheduled conference call and webcast demonstrate the company's commitment to engaging with investors and providing them with direct access to management insights.
- The emphasis on pioneering allogeneic CAR T technology positions Allogene Therapeutics as a leader in innovative cancer and autoimmune disease treatment solutions.
Potential Negatives
- The press release contains a cautionary note on forward-looking statements, suggesting potential risks and uncertainties regarding the development, safety, efficacy, and regulatory approval of their product candidates, which may imply challenges in the company's future operations.
- There is no assurance provided that the company's product candidates will reach commercialization, indicating an inherent risk in their business strategy and investment appeal.
- The press release emphasizes that various factors may cause material differences between expectations and actual results, highlighting a lack of certainty in the company's projected success.
FAQ
When is the Allogene Therapeutics conference call scheduled?
The conference call is scheduled for August 13, 2025, at 2:00 p.m. PT/5:00 p.m. ET.
How can I access the webcast for the earnings release?
The webcast will be available on Allogene Therapeutics' website under the Investors tab in the News and Events section.
Will a replay of the conference call be available?
Yes, a replay of the conference call will be available on the company's website for approximately 30 days.
How can I ask a question during the conference call?
You can register for the conference call using the provided link to receive a personal PIN for access.
What does Allogene Therapeutics specialize in?
Allogene Therapeutics specializes in developing allogeneic CAR T cell products for cancer and autoimmune diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALLO Insider Trading Activity
$ALLO insiders have traded $ALLO stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ALLO stock by insiders over the last 6 months:
- DAVID D CHANG (President and CEO) sold 46,668 shares for an estimated $91,469
- DEBORAH M. MESSEMER sold 13,313 shares for an estimated $32,350
- ANNIE YOSHIYAMA (SVP, Finance) sold 9,601 shares for an estimated $13,537
- BENJAMIN MACHINAS BENESKI (SVP, Chief Technical Officer) sold 5,488 shares for an estimated $10,838
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ALLO Hedge Fund Activity
We have seen 81 institutional investors add shares of $ALLO stock to their portfolio, and 76 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 16,377,833 shares (-68.9%) from their portfolio in Q1 2025, for an estimated $23,911,636
- DARWIN GLOBAL MANAGEMENT, LTD. added 10,449,791 shares (+inf%) to their portfolio in Q1 2025, for an estimated $15,256,694
- CAPITAL WORLD INVESTORS added 5,368,778 shares (+77.8%) to their portfolio in Q1 2025, for an estimated $7,838,415
- CITADEL ADVISORS LLC added 4,854,233 shares (+90.7%) to their portfolio in Q1 2025, for an estimated $7,087,180
- STATE STREET CORP removed 4,460,189 shares (-61.5%) from their portfolio in Q1 2025, for an estimated $6,511,875
- GOLDMAN SACHS GROUP INC added 3,747,397 shares (+177.9%) to their portfolio in Q1 2025, for an estimated $5,471,199
- VESTAL POINT CAPITAL, LP removed 1,500,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,190,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ALLO Analyst Ratings
Wall Street analysts have issued reports on $ALLO in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 05/15/2025
- Truist Securities issued a "Buy" rating on 05/14/2025
- Piper Sandler issued a "Overweight" rating on 05/14/2025
- RBC Capital issued a "Outperform" rating on 05/14/2025
- Oppenheimer issued a "Outperform" rating on 05/14/2025
- Baird issued a "Outperform" rating on 05/14/2025
- HC Wainwright & Co. issued a "Buy" rating on 03/19/2025
To track analyst ratings and price targets for $ALLO, check out Quiver Quantitative's $ALLO forecast page.
$ALLO Price Targets
Multiple analysts have issued price targets for $ALLO recently. We have seen 9 analysts offer price targets for $ALLO in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $4.0 on 05/15/2025
- Asthika Goonewardene from Truist Securities set a target price of $10.0 on 05/14/2025
- Biren Amin from Piper Sandler set a target price of $7.0 on 05/14/2025
- Luca Issi from RBC Capital set a target price of $10.0 on 05/14/2025
- Matthew Biegler from Oppenheimer set a target price of $9.0 on 05/14/2025
- Jack Allen from Baird set a target price of $9.0 on 05/14/2025
- Robert Burns from HC Wainwright & Co. set a target price of $8.0 on 03/19/2025
Full Release
- Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the second quarter 2025 financial results and provide a business update on August 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at
www.allogene.com
under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use
this link
to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T
™
) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit
www.allogene.com
, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Form 10-Q filed for the quarter ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
[email protected]
